CJA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Submit a scholarly reply
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van den Broek, W. W.
Right arrow Articles by Bruijn, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van den Broek, W. W.
Right arrow Articles by Bruijn, J. A.
Canadian Journal of Anesthesia 50:198-199 (2003)
© Canadian Anesthesiologists' Society, 2003


Correspondence

Alfentanil has no proconvulsive effect during electroconvulsive therapy

Walter W. van den Broek, MD, Theo H.N. Groenland, MD, Arinardi Kusuma, MD PhD, Paul G.H. Mulder, PhD and Jan A. Bruijn, MD PhD

Rotterdam The Netherlands

To the Editor:

The efficacy of electroconvulsive therapy (ECT) relates to seizure duration.1 We explored whether alfentanil has an effect on seizure duration during anesthesia for ECT. In addition, we investigated the effects of alfentanil on the cardiovascular response during ECT, and on the duration of apnea. Etomidate was used as the anesthetic agent because it has the least effect on seizure duration compared with methohexital, propofol and thiopentone.2,3

After approval from the Hospital’s Ethics Committee, 21 consecutive patients were studied. In the second and subsequent five sessions patients received iv administration of metoclopramide 10 mg, glycopyrrolate 0.002–0.003 mg.kg-1, a bolus injection of either alfentanil (0.010–0.015 mg.kg-1 ) or placebo (0.9% NaCl) in identical volumes and etomidate 0.2–0.3 mg.kg-1 followed by succinylcholine 0.5–1.0 mg.kg-1. The administration of alfentanil or placebo was done in a double-blind cross-over fashion with four sequences of six periods with two treatments. Blinded syringes were prepared by the pharmacy according to a computer-generated randomization list. Seizure duration was recorded by a two-channel electroencephalograph (EEG). Systolic and diastolic blood pressure (SBP, DBP), mean arterial pressure (MAP) and heart rate (HR) were monitored from arrival in the ECT suite until the patient started breathing adequately. Before the ECT, measurements were made once per minute and continuously thereafter.

Differences in hemodynamic variables, seizure- and apnea duration between the alfentanil and placebo sessions were estimated and tested using mixed model analysis of variance. Blood pressure and HR one hour before each treatment session was taken as covariate.

There was no significant difference in mean seizure duration as measured with EEG between alfentanil and placebo sessions (placebo = 86 sec, alfentanil = 80 sec).

Immediately before and after the stimulus the means of DBP, MAP and HR but not SBP were significantly lower after alfentanil than after placebo (TableGo). Apnea duration in the alfentanil sessions was on average 73 sec longer than in the placebo sessions (standard error = 17.5, P = 0.0001). Alfentanil itself does not lengthen seizure duration in combination with etomidate; it can be used to reduce the dosage of methohexital and propofol in order to prevent the shortening effects on seizures of both anesthetics.4 The small but significant effect of alfentanil on the cardiovascular response, without effect on seizure duration during ECT, could be of benefit for high risk patients with cardiovascular diseases.5


View this table:
[in this window]
[in a new window]
 
TABLE Effect of alfentanil compared with placebo on variables measured before and after the electroconvulsive therapy stimulus; placebo and alfentanil values are baseline-adjusted means estimated over three periods using mixed model ANOVA
 

References

1 Sackeim HA, Prudic J, Devanand DP, et al. Effects of stimulus intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. N Engl J Med 1993; 328: 839–46.[Abstract/Free Full Text]

2 Avramov MN, Husain MM, White PF. The comparative effects of methohexital, propofol, and etomidate for electroconvulsive therapy. Anesth Analg 1995; 81: 596–602.[Abstract]

3 Christensen P, Kragh-Sorensen P, Sorensen C, et al. EEG-monitored ECT: a comparison of seizure duration under anesthesia with etomidate and thiopentone. Convuls Ther 1986; 2: 145–50.[Medline]

4 Nguyen TT, Chhibber AK, Lustik SJ, Kolano JW, Dillon PJ, Guttmacher LB. Effect of methohexitone and propofol with or without alfentanil on seizure duration and recovery in electroconvulsive therapy. Br J Anaesth 1997; 79: 801–3.[Abstract/Free Full Text]

5 van den Broek WW, Leentjens AF, Mulder PG, Kusuma A, Bruijn JA. Low-dose esmolol bolus reduces seizure duration during electroconvulsive therapy: a double-blind, placebo-controlled study. Br J Anaesth 1999; 83: 271–4.[Abstract/Free Full Text]





This Article
Right arrow Full Text (PDF)
Right arrow Submit a scholarly reply
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van den Broek, W. W.
Right arrow Articles by Bruijn, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van den Broek, W. W.
Right arrow Articles by Bruijn, J. A.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS